CLOSTNET

A Clostridal Biology Network to Facilitate European-wide Medical Countermeasures and Commercial Exploitation

 Coordinatore THE UNIVERSITY OF NOTTINGHAM 

 Organization address address: University Park
city: NOTTINGHAM
postcode: NG7 2RD

contact info
Titolo: Mr.
Nome: Paul
Cognome: Cartledge
Email: send email
Telefono: +44 115 9515679
Fax: +44 115 9513633

 Nazionalità Coordinatore United Kingdom [UK]
 Totale costo 4˙811˙791 €
 EC contributo 4˙811˙791 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-ITN-2008
 Funding Scheme MC-ITN
 Anno di inizio 2009
 Periodo (anno-mese-giorno) 2009-09-01   -   2013-08-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    THE UNIVERSITY OF NOTTINGHAM

 Organization address address: University Park
city: NOTTINGHAM
postcode: NG7 2RD

contact info
Titolo: Mr.
Nome: Paul
Cognome: Cartledge
Email: send email
Telefono: +44 115 9515679
Fax: +44 115 9513633

UK (NOTTINGHAM) coordinator 534˙256.80
2    HELSINGIN YLIOPISTO

 Organization address address: YLIOPISTONKATU 4
city: HELSINGIN YLIOPISTO
postcode: 14

contact info
Titolo: Ms.
Nome: Katariina
Cognome: Vainio-Mattila
Email: send email
Telefono: 358054000000
Fax: 358919000000

FI (HELSINGIN YLIOPISTO) participant 453˙389.92
3    THE UNIVERSITY OF EXETER

 Organization address address: Northcote House, The Queen's Drive
city: EXETER
postcode: EX4 4QJ

contact info
Titolo: Dr.
Nome: Enda
Cognome: Clarke
Email: send email
Telefono: +44 1392 263744
Fax: +44 1392 263686

UK (EXETER) participant 444˙925.65
4    UNILEVER U.K. CENTRAL RESOURCES LIMITED

 Organization address address: "UNILEVER HOUSE, VICTORIA EMBANKMENT 100"
city: LONDON
postcode: EC4Y 0DY

contact info
Titolo: Dr.
Nome: Peter
Cognome: Mcclure
Email: send email
Telefono: +44 1234 264788
Fax: +44 1234 264929

UK (LONDON) participant 440˙760.32
5    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

 Organization address address: Rue Michel -Ange 3
city: PARIS
postcode: 75794

contact info
Titolo: Ms.
Nome: Beatrice
Cognome: Saint Cricq
Email: send email
Telefono: +33 4 91 16 4008
Fax: +33 4 91 16 9304

FR (PARIS) participant 437˙562.92
6    METABOLIC EXPLORER SA

 Organization address address: BIOPOLE CLERMONT LIMAGNE
city: SAINT BEAUZIRE
postcode: 63360

contact info
Titolo: Mr.
Nome: Paul
Cognome: Michalet
Email: send email
Telefono: +33 473 334 300
Fax: +33 473 334 301

FR (SAINT BEAUZIRE) participant 430˙416.47
7    ISTITUTO SUPERIORE DI SANITA

 Organization address address: Viale Regina Elena 299
city: ROMA
postcode: 161

contact info
Titolo: Dr.
Nome: Rosa Maria
Cognome: Martoccia
Email: send email
Telefono: +3906 49902688
Fax: +39 06 49903007

IT (ROMA) participant 428˙903.81
8    TECHNISCHE UNIVERSITAET MUENCHEN

 Organization address address: Arcisstrasse 21
city: MUENCHEN
postcode: 80333

contact info
Titolo: Ms.
Nome: Ulrike
Cognome: Ronchetti
Email: send email
Telefono: 498929000000
Fax: 498929000000

DE (MUENCHEN) participant 428˙796.63
9    UNIVERSITAET ROSTOCK

 Organization address address: UNIVERSITATSPLATZ 1
city: ROSTOCK
postcode: 18051

contact info
Titolo: Ms.
Nome: Ursula
Cognome: Kessler
Email: send email
Telefono: 493815000000
Fax: 493815000000

DE (ROSTOCK) participant 428˙796.63
10    GLAXOSMITHKLINE VACCINES SRL

 Organization address address: Via Fiorentina 1
city: SIENA
postcode: 53100

contact info
Titolo: Dr.
Nome: Gulli
Cognome: Francesco
Email: send email
Telefono: +39 0577 243089
Fax: +39 0577 243085

IT (SIENA) participant 424˙908.42
11    ZAVOD ZA ZDRAVSTVENO VARSTVO MARIBOR

 Organization address address: PRVOMAJSKA 1 1
city: MARIBOR
postcode: 2000

contact info
Titolo: Ms.
Nome: Melita
Cognome: Kores
Email: send email
Telefono: 38624500254
Fax: 38624500225

SI (MARIBOR) participant 359˙073.43
12    Intervet International B.V.

 Organization address address: WIM DE KORVERSTRAAT 35
city: BOXMEER
postcode: 5831 AN

contact info
Titolo: Mr.
Nome: Mark
Cognome: Van Heumen
Email: send email
Telefono: +31 485 58 7086
Fax: +31 485 58 7075

NL (BOXMEER) participant 0.00
13    Phico Therapeutics Ltd

 Organization address address: Babraham Research Campus
city: Babraham
postcode: CB22 3AT

contact info
Titolo: Dr.
Nome: Heather
Cognome: Fairhead
Email: send email
Telefono: +44 1223 496562
Fax: -+44 1223 496018

UK (Babraham) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

species    academia    difficile    clostridia    botulinum    world    inadequate    basic    inactivation    acetobutylicum    therapy    excellence    progress    diseases    industry    biofuel    young    fragmented    biology    scientific    lack    sporogenes    network    sectors    multidisciplinary    impeded    gene    vaccine    clostridial    cancer    efforts    pathogenic    clostnet    pathogens   

 Obiettivo del progetto (Objective)

'There is an urgent need to better understand the basic biology of Clostridium as a prerequisite for both countering the diseases they cause (C.difficile, C.perfringens and C.botulinum), and exploiting their beneficial properties in industry (biofuels by C.acetobutylicum) and medicine (cancer therapy by C.sporogenes). Attainment of this goal is being impeded because: (i) European research efforts are fragmented; (ii) there is no coherence between researchers working on pathogenic species and industrially important strains; (iii) there is a demonstrable (SCF-CT-2005-029958) lack of trained young clostridial researchers; (iv) there is inadequate networking between industry and academia, and; (v) effective exploitation of the amassed clostridial genome data has been precluded by a woeful inadequacy in procedures for gene inactivation. Removal of these impediments cannot be achieved at a national level, but requires the creation of a transnational network of multi-disciplinary experts,active in different scientific sectors. The technical hurdle to progress has now been solved by partner 1, who has developed a highly effective andreproducible gene knock-out system. The remaining hurdles will be overcome by bringing together a multidisciplinary team of research expertise from 7 different EU states drawn from Academia (5), Government (3) and different sectors of Industry (3). A principal focus will be to address the deficiency in critical mass by providing young researchers with world class, state-of-the-art, multidisciplinary training in leading scientific and biotechnological skills that have relevance to medical countermeasures against pathogens and the exploitation of non-pathogens in industrial processes and disease intervention. These measures will establish Europe as a ‘Centre of Excellence’ for clostridial research, propelling the community to the forefront of the field, eclipsing the efforts of the rest of the world, and in particular the USA and Japan.'

Introduzione (Teaser)

A European alliance worked on the biology of Clostridia species. The results have important implications for tackling Clostridia pathogenicity and for enhancing the commercial exploitation of non-pathogenic species.

Descrizione progetto (Article)

Clostridia are a heterogeneous group of bacteria with diverse actions. They cause diseases such as tetanus and botulism (C. difficile and C. botulinum) but can also be used to treat cancer (C. sporogenes and C. novyi). Also certain Clostridia species are used in the industry for biofuel production such as in the case of C. acetobutylicum.

Despite their importance, the basic biology of Clostridia has not been fully elucidated due to fragmented research efforts and lack of communication with the industry. Additionally, inadequate procedures for gene inactivation have impeded the progress of Clostridia-related research. To address these issues, the EU-funded http://www.clostridia.net/clostnet/index.html (CLOSTNET) consortium brought together 11 Centres of Excellence in academia and industry, across seven different EU countries. The idea was to train new researchers in the field while delineating key aspects in Clostridia biology.

One of the project partners developed the revolutionary ClostTron technology. This technology has made it possible to systematically inactivate genes and evaluate their function. Using this unique tool, scientists identified a negative regulator of the botulinum neurotoxin, offering hope for the development of an anti-toxin remedy.

Further characterisation of Clostridia led to the identification of virulent factors and novel targets for vaccine development. Given the role of C.difficile in hospital infections, particular emphasis was given on its ability to form biofilms and the genetic determinants of this capacity.

With respect to the utilisation of Clostridia in industry, researchers identified new systems involved in regulating production of the biofuel butanol in C. acetobutylicum. These regulatory elements could be commercially exploited to enhance biofuel production.

The network on Clostridia research has undoubtedly produced a series of key findings that improve our understanding of Clostridia biology. Implementation of these results in diagnosis, vaccine development and cancer therapy is expected to improve the health of European citizens.

Altri progetti dello stesso programma (FP7-PEOPLE)

COMBATING SEPSIS (2007)

WHY DO THEY DIE? DECIPHERING AND QUELLING THE LETHAL CUES OF IMMUNO-INFLAMMATORY RESPONSE IN SEPSIS

Read More  

PYROGAS (2012)

The integration of intermediate pyrolysis and vapour gasification to create and effective and efficient biomass-to-energy system for combined heat and power

Read More  

HLTAUS (2014)

A Level-1 Tau Trigger for CMS at HL-LHC

Read More